Sexual function in men with metabolic syndrome

Urologic Clinics of North America

Volumn 39, Issue 1, 2012, Pages 53-62

  Lee, Richard K ^a   Chughtai, Bilal ^a   Te, Alexis E ^a   Kaplan, Steven A ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Metabolic syndrome X; Obesity; Overactive; Physiologic; Sexual dysfunction; Urinary bladder; Waist circumference

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIHYPERTENSIVE AGENT; AROMATASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRADIOL; ESTROGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; LETROZOLE; METFORMIN; NITRIC OXIDE; PLACEBO; SILDENAFIL; TADALAFIL; TESTOLACTONE; TESTOSTERONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VARDENAFIL;

ANDROGEN THERAPY; ATHEROSCLEROSIS; BARIATRIC SURGERY; CALORIC RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; EXERCISE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; LIFESTYLE MODIFICATION; MALE; MALE SEXUAL DYSFUNCTION; MEDITERRANEAN DIET; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT COMPLIANCE; PENIS PROSTHESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROUX Y ANASTOMOSIS; SENSORY NEUROPATHY; SEXUAL SATISFACTION; WAIST HIP RATIO; WEIGHT REDUCTION;

ADULT; AGE DISTRIBUTION; AGED; COMORBIDITY; ERECTILE DYSFUNCTION; HUMANS; HYPOGONADISM; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; UNITED STATES;

EID: 82455181444     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2011.09.008     Document Type: Review

References (91)

1. Corona G., Mannucci E., Forti G., et al. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl 2009, 32(6):587-598.
2. Balkau B., Charles M.A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999, 16(5):442-443.
3. Einhorn D., Reaven G.M., Cobin R.H., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003, 9(3):237-252.
4. Executive summary of the third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285(19):2486-2497.
5. Adams R.J., Appleton S., Wilson D.H., et al. Population comparison of two clinical approaches to the metabolic syndrome: implications of the new International Diabetes Federation consensus definition. Diabetes Care 2005, 28(11):2777-2779.
6. Chang S.T., Chu C.M., Pan K.L., et al. Prevalence and cardiovascular disease risk differences for erectile dysfunction patients by three metabolic syndrome definitions. Int J Impot Res 2011, 23(2):87-93.
7. Guay A., Jacobson J. The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction. J Sex Med 2007, 4(4 Pt 1):1046-1055.
8. Huang P.L. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009, 2(5-6):231-237.
9. Corona G., Mannucci E., Petrone L., et al. A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction. J Sex Med 2007, 4(3):789-796.
10. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. Wolrd Health Organ Tech Rep Ser 2000, 894(1-12):1-253. WHO Consultation on Obesity.
11. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002, 288(14):1723-1727.
12. Sturm R. Increases in clinically severe obesity in the United States, 1986-2000. Arch Intern Med 2003, 163(18):2146-2148.
13. Ruhm CJ. Current and future prevalence of obesity and severe obesity in the United States. Forum for Health Economics & Policy 2007;10(2)(Obesity):Article 6.
14. Golden S.H., Robinson K.A., Saldanha I., et al. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009, 94(6):1853-1878.
15. Deckelbaum R.J., Williams C.L. Childhood obesity: the health issue. Obes Res 2001, 9(Suppl 4):239S-243S.
16. Corona G., Mannucci E., Petrone L., et al. NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J Sex Med 2007, 4(4 Pt 1):1038-1045.
17. Corona G., Mannucci E., Schulman C., et al. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol 2006, 50(3):595-604. [discussion: 604].
18. Gunduz M.I., Gumus B.H., Sekuri C. Relationship between metabolic syndrome and erectile dysfunction. Asian J Androl 2004, 6(4):355-358.
19. Esposito K., Giugliano F., Martedi E., et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 2005, 28(5):1201-1203.
20. Demir T., Demir O., Kefi A., et al. Prevalence of erectile dysfunction in patients with metabolic syndrome. Int J Urol 2006, 13(4):385-388.
21. Kupelian V., Shabsigh R., Araujo A.B., et al. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol 2006, 176(1):222-226.
22. Grover S.A., Lowensteyn I., Kaouache M., et al. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med 2006, 166(2):213-219.
23. Heidler S., Temml C., Broessner C., et al. Is the metabolic syndrome an independent risk factor for erectile dysfunction?. J Urol 2007, 177(2):651-654.
24. Bal K., Oder M., Sahin A.S., et al. Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: metabolic backgrounds of erectile dysfunction. Urology 2007, 69(2):356-360.
25. Yeh H.C., Wang C.J., Lee Y.C., et al. Association among metabolic syndrome, testosterone level and severity of erectile dysfunction. Kaohsiung J Med Sci 2008, 24(5):240-247.
26. Corona G., Mannucci E., Ricca V., et al. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl 2009, 32(6):720-728.
27. Reilly C.M., Zamorano P., Stopper V.S., et al. Androgenic regulation of NO availability in rat penile erection. J Androl 1997, 18(2):110-115.
28. Blumentals W.A., Gomez-Caminero A., Joo S., et al. Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int J Impot Res 2004, 16(4):350-353.
29. Nehra A., Azadzoi K.M., Moreland R.B., et al. Cavernosal expandability is an erectile tissue mechanical property which predicts trabecular histology in an animal model of vasculogenic erectile dysfunction. J Urol 1998, 159(6):2229-2236.
30. Koca O., Caliskan S., Ozturk M.I., et al. Vasculogenic erectile dysfunction and metabolic syndrome. J Sex Med 2010, 7(12):3997-4002.
31. Beckman J.A., Goldfine A.B., Gordon M.B., et al. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 2001, 103(12):1618-1623.
32. Nishikawa T., Edelstein D., Du X.L., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404(6779):787-790.
33. Creager M.A., Luscher T.F., Cosentino F., et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 2003, 108(12):1527-1532.
34. Jiaan D.B., Seftel A.D., Fogarty J., et al. Age-related increase in an advanced glycation end product in penile tissue. World J Urol 1995, 13(6):369-375.
35. Arana Rosainz M.D., Ojeda M.O., Acosta J.R., et al. Imbalanced low-grade inflammation and endothelial activation in patients with type 2 diabetes mellitus and erectile dysfunction. J Sex Med 2011, 8(7):2017-2030.
36. Pohjantähti-Maaroos H., Palomaki A. Comparison of metabolic syndrome subjects with and without erectile dysfunction - levels of circulating oxidised LDL and arterial elasticity. Int J Clin Pract 2011, 65(3):274-280.
37. Bemelmans B.L., Meuleman E.J., Doesburg W.H., et al. Erectile dysfunction in diabetic men: the neurological factor revisited. J Urol 1994, 151(4):884-889.
38. Fonseca V., Jawa A. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments?. Am J Cardiol 2005, 96(12B):13M-18M.
39. Vermeulen A. Androgen replacement therapy in the aging male-a critical evaluation. J Clin Endocrinol Metab 2001, 86(6):2380-2390.
40. Petak S.M., Nankin H.R., Spark R.F., et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract 2002, 8(6):440-456.
41. Kelleher S., Conway A.J., Handelsman D.J. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004, 89(8):3813-3817.
42. Corona G., Monami M., Rastrelli G., et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011, 8(1):272-283.
43. Kaplan S.A., Meehan A.G., Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?. J Urol 2006, 176(4 Pt 1):1524-1527. [discussion: 1527-8].
44. Kupelian V., Hayes F.J., Link C.L., et al. Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. J Clin Endocrinol Metab 2008, 93(9):3403-3410.
45. Goncharov N.P., Katsya G.V., Chagina N.A., et al. Three definitions of metabolic syndrome applied to a sample of young obese men and their relation with plasma testosterone. Aging Male 2008, 11(3):118-122.
46. Kapoor D., Clarke S., Stanworth R., et al. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007, 156(5):595-602.
47. Lee M.J., Fried S.K. Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion. Am J Physiol Endocrinol Metab 2009, 296(6):E1230-E1238.
48. McConway M.G., Johnson D., Kelly A., et al. Differences in circulating concentrations of total, free and bound leptin relate to gender and body composition in adult humans. Ann Clin Biochem 2000, 37(Pt 5):717-723.
49. Luukkaa V., Pesonen U., Huhtaniemi I., et al. Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab 1998, 83(9):3243-3246.
50. Isidori A.M., Caprio M., Strollo F., et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999, 84(10):3673-3680.
51. Caprio M., Isidori A.M., Carta A.R., et al. Expression of functional leptin receptors in rodent Leydig cells. Endocrinology 1999, 140(11):4939-4947.
52. Kalyani R.R., Dobs A.S. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007, 14(3):226-234.
53. Hong C.Y., Park J.H., Ahn R.S., et al. Molecular mechanism of suppression of testicular steroidogenesis by proinflammatory cytokine tumor necrosis factor alpha. Mol Cell Biol 2004, 24(7):2593-2604.
54. Lin T., Wang D., Stocco D.M. Interleukin-1 inhibits Leydig cell steroidogenesis without affecting steroidogenic acute regulatory protein messenger ribonucleic acid or protein levels. J Endocrinol 1998, 156(3):461-467.
55. Vermeulen A., Kaufman J.M., Deslypere J.P., et al. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 1993, 76(5):1140-1146.
56. Loves S., Ruinemans-Koerts J., de Boer H. Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol 2008, 158(5):741-747.
57. Zumoff B., Miller L.K., Strain G.W. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 2003, 52(9):1126-1128.
58. Cohen P.G. Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis. Med Hypotheses 2008, 70(2):358-360.
59. Kupelian V., Page S.T., Araujo A.B., et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006, 91(3):843-850.
60. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346(6):393-403.
61. Esposito K., Giugliano F., Di Palo C., et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004, 291(24):2978-2984.
62. Esposito K., Pontillo A., Di Palo C., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289(14):1799-1804.
63. Esposito K., Marfella R., Ciotola M., et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004, 292(12):1440-1446.
64. Esposito K., Ciotola M., Giugliano F., et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res 2006, 18(4):405-410.
65. Goldstein M.G., Niaura R. Methods to enhance smoking cessation after myocardial infarction. Med Clin North Am 2000, 84(1):63-80. viii.
66. Borges R., Temido P., Sousa L., et al. Metabolic syndrome and sexual (dys)function. J Sex Med 2009, 6(11):2958-2975.
67. Kim Y.W., Park S.Y., Kim J.Y., et al. Metformin restores the penile expression of nitric oxide synthase in high-fat-fed obese rats. J Androl 2007, 28(4):555-560.
68. Goldstein I., Lue T.F., Padma-Nathan H., et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998, 338(20):1397-1404.
69. Carson C.C., Burnett A.L., Levine L.A., et al. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002, 60(2 Suppl 2):12-27.
70. Brock G.B., McMahon C.G., Chen K.K., et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002, 168(4 Pt 1):1332-1336.
71. Kloner R.A. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 2005, 96(12B):42M-46M.
72. Corona G., Razzoli E., Forti G., et al. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 2008, 31(9):799-808.
73. Kapoor D., Goodwin E., Channer K.S., et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006, 154(6):899-906.
74. Boyanov M.A., Boneva Z., Christov V.G. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003, 6(1):1-7.
75. Saad F., Gooren L., Haider A., et al. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl 2007, 53(6):353-357.
76. Permpongkosol S., Tantirangsee N., Ratana-olarn K. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints. J Sex Med 2010, 7(11):3765-3774.
77. Heufelder A.E., Saad F., Bunck M.C., et al. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009, 30(6):726-733.
78. La Vignera S., Calogero A.E., D'Agata R., et al. Testosterone therapy improves the clinical response to conventional treatment for male patients with metabolic syndrome associated to late onset hypogonadism. Minerva Endocrinol 2008, 33(3):159-167.
79. Aversa A., Bruzziches R., Francomano D., et al. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest 2010, 33(11):776-783.
80. Tishova Y., Kalinchenko S.Y., Mskhalaya G.J., et al. The Moscow Study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the metabolic syndrome components and body composition. Endocr Abstr 2010, 22:681.
81. Basaria S., Coviello A.D., Travison T.G., et al. Adverse events associated with testosterone administration. N Engl J Med 2010, 363(2):109-122.
82. Wang C., Nieschlag E., Swerdloff R., et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res 2009, 21(1):1-8.
83. American Society for Metabolic and Bariatric Surgery Rationale for the surgical treatment of morbid obesity Available at:, Accessed May 1, 2011. http://www.asbs.org/Newsite07/patients/resources/asbs_rationale.htm.
84. Gahtan V.V., Kurto H.Z., Powers P.S., et al. Changes in sexual patterns following vertical banded gastroplasty and weight loss. Obes Surg 1992, 2(1):97-99.
85. Camps M.A., Zervos E., Goode S., et al. Impact of bariatric surgery on body image perception and sexuality in morbidly obese patients and their partners. Obes Surg 1996, 6(4):356-360.
86. Hafner R.J., Watts J.M., Rogers J. Quality of life after gastric bypass for morbid obesity. Int J Obes 1991, 15(8):555-560.
87. Dallal R.M., Chernoff A., O'Leary M.P., et al. Sexual dysfunction is common in the morbidly obese male and improves after gastric bypass surgery. J Am Coll Surg 2008, 207(6):859-864.
88. di Frega A.S., Dale B., Di Matteo L., et al. Secondary male factor infertility after Roux-en-Y gastric bypass for morbid obesity: case report. Hum Reprod 2005, 20(4):997-998.
89. Vazquez C., Morejon E., Munoz C., et al. Nutr Hosp 2003, 18(4):189-193. [in Spanish].
90. Scott F.B., Bradley W.E., Timm G.W. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology 1973, 2(1):80-82.
91. Montague D. Prosthetic surgery for erectile dysfunction. Campbell's urology 2011, vol. 1:788-801. Elsevier, Philadelphia. A. Wein (Ed.).